Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

QR Code

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

Martha Sajatovic,1,2 Ruth Ross,3 Susan N Legacy,4 Christoph U Correll,5,6 John M Kane,5,6 Faith DiBiasi,7 Heather Fitzgerald,8 Matthew Byerly9 1Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; 2Departments of Psychiatry and Neurology, Case Western Reserve...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2018
Sujets:	expert consensus schizophrenia schizoaffective disorder bipolar disorder long-acting injectable antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/71a5f44f201f4553ac0ebe5e8a53449b
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
par: Sajatovic M, et autres
Publié: (2018)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review
par: Sajatovic M, et autres
Publié: (2017)

Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
par: L. A. Ivanova, et autres
Publié: (2019)

Patterns of Thyroid Hormone Prescription in Patients with Bipolar or Schizoaffective Disorder: Findings from the LiSIE Retrospective Cohort Study
par: Ingrid Lieber, et autres
Publié: (2021)

Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
par: Bracha Erlanger Avigdor, et autres
Publié: (2021)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
par: Cuomo I, et autres
Publié: (2018)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
par: Montemagni C, et autres
Publié: (2016)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
par: Fitzgerald HM, et autres
Publié: (2021)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2019)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
par: de Bartolomeis A, et autres
Publié: (2016)

Overcoming barriers to effective management of tardive dyskinesia
par: Caroff SN
Publié: (2019)

Association of carbohydrate and fatty acid intake with anthropometric parameters in subjects with schizophrenia and bipolar disorders
par: Santillana T,Natalia, et autres
Publié: (2016)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
par: Ohnishi T, et autres
Publié: (2021)

When should a psychiatrist remember to test homocysteine levels? - a literature review
par: Nowak Katarzyna, et autres
Publié: (2021)

Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus study
par: Jennings AA, et autres
Publié: (2018)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
par: Pietrini F, et autres
Publié: (2019)

Identification of Rare Mutations of Two Presynaptic Cytomatrix Genes <i>BSN</i> and <i>PCLO</i> in Schizophrenia and Bipolar Disorder
par: Chia-Hsiang Chen, et autres
Publié: (2021)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
par: Patrick Köck, et autres
Publié: (2021)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
par: Faden J, et autres
Publié: (2019)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
par: Hýža M, et autres
Publié: (2021)

Alcohol dependence is formed on the background of violations of mental adaptation
par: T. V. Agibalova, et autres
Publié: (2013)

Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2020)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
par: Madera JJ, et autres
Publié: (2019)

Consensus on the Treatment of Adrenocortical Carcinoma with Mitotane(2021)
par: Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital
Publié: (2021)

Evaluación de la calidad de vida de pacientes bipolares chilenos: propiedades psicométricas y utilidad diagnóstica de la versión chilena del cuestionario Quality of Life Bipolar Disorder (QoL.BD-CL)
par: Morgado,Carolina, et autres
Publié: (2015)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
par: Chiu LL, et autres
Publié: (2019)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
par: Suda A, et autres
Publié: (2018)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
par: Borjanka Batinic, et autres
Publié: (2021)

Virginia Woolf: enfermedad mental y creatividad artística
par: Figueroa C,Gustavo
Publié: (2005)

Atypical antipsychotics as add-on treatment in late-life depression
par: Cakir S, et autres
Publié: (2016)

Exercise for Neuropathic Pain: A Systematic Review and Expert Consensus
par: Yong-Hui Zhang, et autres
Publié: (2021)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
par: Madera J, et autres
Publié: (2019)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
par: Leonid Mikhaylovich Bardenshteyn, et autres
Publié: (2010)

Use of atypical antipsychotics in the elderly: a clinical review
par: Gareri P, et autres
Publié: (2014)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
par: Tzu-Pei Yeh, et autres
Publié: (2021)

Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
par: Yalin N, et autres
Publié: (2020)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
par: Stephan Hjorth, et autres
Publié: (2021)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
par: Peters-Strickland T, et autres
Publié: (2019)

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
par: Findling RL, et autres
Publié: (2018)